Dupilumab Improves Health-Related Quality of Life (HRQoL) and Reduces Symptom Burden in Patients with Eosinophilic Esophagitis (EoE): Results From Part A of a Randomized, Placebo-Controlled Three-Part Phase 3 Study
Evan S. Dellon(University of North Carolina at Chapel Hill), Siddhesh Kamat(Regeneron (United States)), Elizabeth Laws(Sanofi (United States)), Jennifer Maloney(Regeneron (United States)), Albert J. Bredenoord(Amsterdam Neuroscience), Bethany Beazley(Regeneron (United States)), Jonathan M. Spergel(University of Pennsylvania), Brad Shumel(Regeneron (United States)), Leda Mannent(Sanofi (France)), Marc E. Rothenberg(Cincinnati Children's Hospital Medical Center), Nikhil Amin(Regeneron (United States)), Qiong Zhao(Regeneron (United States)), Isabelle Guillemin, Mirna Chehade(Icahn School of Medicine at Mount Sinai), Ikuo Hirano(Northwestern University)
Cited by 13
Related Papers
Eosinophilic esophagitis: Updated consensus recommendations for children and adults
|Journal of Allergy and Clinical Immunology|2011|2.1k
Burden of Gastrointestinal Disease in the United States: 2012 Update
|Gastroenterology|2012|2k
Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018
|Gastroenterology|2018|1.7k
Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference
|Gastroenterology|2018|1.1k
Burden of Gastrointestinal, Liver, and Pancreatic Diseases in the United States
|Gastroenterology|2015|996